Thanks for the excellent support and participation in 2024.
Please accept the Executives’ wishes for good health and memorable times with family and friends in 2025. Dr Tamm advised us that the Canadian Association of Nuclear Medicine has reached agreement with Novartis to include a new drug (Pluvicto) in the treatment of metastatic castration resistant prostate cancer (cancer that has spread beyond the prostate). This is a precision cancer treatment that uses a radioactive particle (lutetium 177) that binds to prostate cancer cells that express PSMA. The radioisotope attaches to the target cells and damages them, disrupting their ability to replicate. This is a game changer for men that have had PC escape the prostate gland.
There will be a bit of a delay before Pluvicto is available as each Province has to follow protocols to use it as a treatment modality. A reasonable guess before it is available would be 6 months from this date.
Stephanie Weimar contacted me seeking men in our Society that may be interested in participating in a short film to speak of their experience in the Canadian healthcare system. As the “wait” list continues to grow for PC treatment, this would be an effective lobby for improvement.
Producer – award winning Jamie Kastner (https://cave7productions.com/
Stephanie Weimar – writer / director / story editor. stephanie.wiemar@gmail.com / 416 827-4277. Contact Stephanie for more details.
We have several men in the Society that are excellent speakers that know their subject well. Give this opportunity some consideration. It might be your first step to possible fame.
